相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
Ibai Goicoechea et al.
BLOOD (2021)
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results
Murielle Roussel et al.
BLOOD (2021)
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial
Ola Landgren et al.
JAMA ONCOLOGY (2021)
Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).
Kwee Yong et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.
Francesca Gay et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2.
Philippe Moreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.
Martin F. Kaiser et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Stefania Oliva et al.
BLOOD CANCER JOURNAL (2021)
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial
Sergio Giralt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients
Joanna Blocka et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Nisha S. Joseph et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).
Parameswaran Hari et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jagoda K. Jasielec et al.
BLOOD (2020)
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
Nadine Abdallah et al.
BLOOD ADVANCES (2020)
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis
Benjamin A. Derman et al.
BLOOD CANCER JOURNAL (2020)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors A Systematic Review and Meta-analysis
Smith Giri et al.
JAMA ONCOLOGY (2020)
Defining and Managing High-Risk Multiple Myeloma: Current Concepts
Luciano J. Costa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
Saad Z Usmani et al.
Lancet Haematology (2020)
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C. Munshi et al.
BLOOD ADVANCES (2020)
Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial
Stefania Oliva et al.
BLOOD (2020)
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Followup Analysis of the IFM 2009 Trial
Aurore Perrot et al.
BLOOD (2020)
A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform
Mattia D'Agostino et al.
BLOOD (2020)
Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
Francesca Gay et al.
BLOOD (2020)
Revealing the Impact of Structural Variants in Multiple Myeloma
Even H. Rustad et al.
BLOOD CANCER DISCOVERY (2020)
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Brian A. Walker et al.
LEUKEMIA (2019)
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
Qaiser Bashir et al.
LANCET HAEMATOLOGY (2019)
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Aurore Perrot et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Benjamin G. Barwick et al.
NATURE COMMUNICATIONS (2019)
Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Nico Gagelmann et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
Katarina Uttervall et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
Antonio Giovanni Solimando et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
Timothy M. Schmidt et al.
BLOOD CANCER JOURNAL (2019)
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Luciano J. Costa et al.
BLOOD (2019)
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Edward A. Stadtmauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos et al.
LANCET (2019)
Impact of acquired del(17p) in multiple myeloma
Arjun Lakshman et al.
BLOOD ADVANCES (2019)
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
V. Shah et al.
LEUKEMIA (2018)
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial
H. Goldschmidt et al.
LEUKEMIA (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al.
BLOOD (2018)
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial
Dickran Kazandjian et al.
JAMA ONCOLOGY (2018)
Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies
Michele Cavo et al.
BLOOD (2018)
Genomic complexity of multiple myeloma and its clinical implications
Salomon Manier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Juan-Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
M. Binder et al.
BLOOD CANCER JOURNAL (2017)
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
Erik H. van Beers et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Bruno Paiva et al.
BLOOD (2016)
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau et al.
BLOOD (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial
Elias K. Mai et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
Michele Cavo et al.
BLOOD (2016)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
Brian A. Walker et al.
NATURE COMMUNICATIONS (2015)
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde et al.
JAMA ONCOLOGY (2015)
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
Pieter Sonneveld et al.
BLOOD (2015)
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma
Isabella C. Glitza et al.
LEUKEMIA & LYMPHOMA (2015)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
M. Affer et al.
LEUKEMIA (2014)
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
P. Leif Bergsagel et al.
BLOOD (2013)
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Gosta Gahrton et al.
BLOOD (2013)
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
A. Keith Stewart et al.
BLOOD (2013)
Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment
K. E. Armeson et al.
BONE MARROW TRANSPLANTATION (2013)
Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
Gareth J. Morgan et al.
CLINICAL CANCER RESEARCH (2013)
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
Mohamed A. Kharfan-Dabaja et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
H. Avet-Loiseau et al.
LEUKEMIA (2013)
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
X. Leleu et al.
LEUKEMIA (2013)
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
Henk M. Lokhorst et al.
BLOOD (2012)
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma
Luisa Giaccone et al.
BLOOD (2011)
Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients
Florence Magrangeas et al.
BLOOD (2011)
Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
Kevin D. Boyd et al.
CLINICAL CANCER RESEARCH (2011)
Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up
Bo Bjorkstrand et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Amrita Krishnan et al.
LANCET ONCOLOGY (2011)
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
M. Varettoni et al.
ANNALS OF ONCOLOGY (2010)
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Brian A. Walker et al.
BLOOD (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosinol et al.
BLOOD (2008)
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma
David Gonzalez et al.
BLOOD (2007)
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
P. Moreau et al.
LEUKEMIA (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
HM Lokhorst et al.
BLOOD (2004)
Single versus double autologous stem-cell transplantation for multiple myeloma
M Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
R Fonseca et al.
BLOOD (2003)
分享论文
